ARCHIVES

Tivozanib Trumps Sorafenib In 1st-Line Renal Cancer Study

This article is from The Cancer Letter archive.

Vol. 35 No. 5 | May 25, 2012

Download PDF Visit The Full Archive

Related Articles

Overdiagnosis Since Advent Of Prostate Cancer Screening

September 25, 2009

Large Pregnancy Weight Gain Raises Risk For Breast Cancer

May 31, 2002

FDA will return memento given to McClellan by NCI Director Andrew von Eschenbach.

February 6, 2004

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

July 31, 2009

FDA Committee to Discuss Policy On Combinations

January 7, 1977

Diet Supplements Should Be Held To Scientific Standards, Broder Tells House

August 6, 1993